Ascentage Pharma Group International (HK:6855) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Ascentage Pharma Group International excitedly reports on the anticipated presentation of their latest clinical study results for three leading drug candidates at the 2024 American Society of Clinical Oncology Annual Meeting. These drugs include the China-approved olverembatinib and other investigational treatments targeting various cancers. The findings will be shared through oral reports and poster presentations, highlighting the company’s advancements in oncology.
For further insights into HK:6855 stock, check out TipRanks’ Stock Analysis page.